Who We Are
Rejuvaline Medical Research participates in clinical trials of new investigational medications and therapies. Josefa L. Binker, M.D. has been practicing medicine for over 46 years. As the Principle Investigator for Rejuvaline Medical Research, Dr. Josefa L. Binker, has overseen and conducted an average of 100 clinical research trials since 2006. At this multi-specialty site, our physician specializes in family practice, dermatology and gynecology. We're a private, research center with 8 full-time research staff members who are completely dedicated and trained to conduct clinical trials. Our facility includes exam rooms, a room dedicated for pharmaceutical company monitors and adequate storage space.
Our trained and knowledgeable staff has over 12 years experience in the area of clinical research. We hold our ethical standards and study completion foremost as we strive to complete our studies in a timely and productive manner. Our qualified medical team and the motivation of our study coordinators give us the ability to accurately and effectively complete our clinical studies.
Our team is diligently looking to discover new ways to improve the lives of the people through pharmaceutical research to defeat deceases and offer the patient the quality of life they deserve!
Our doctors have more than 20 years of combined experience in medical research and are dedicated to providing quality, compassionate care to our patients.
How do clinical trials work and who can participate?
Clinical trials are research studies that aim to determine if treatment of a medical strategy will be safe to for human consumption. To assess if the medical approach for a specific condition or disease will be effective, the studies take place with small groups of people to determine participant safety. The information gathered from this group will then help assist in the decision-making healthcare decision-making guidelines.
Studies Currently In Process
- MK-8835-004/B1521021: Randomized, double-blind, placebo-controlled, parallel-group study to assess cardiovascular outcomes following treatment with ertugliflozin (mk-8835/pf-04971729) in subjects with type 2 diabetes mellitus and established vascular disease.